Cargando…

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain

MYD88 is the key signaling adaptor-protein for Toll-like and interleukin-1 receptors. A somatic L265P mutation within the Toll/interleukin-1 receptor (TIR) domain of MYD88 is found in 90% of Waldenström macroglobulinemia cases and in a significant subset of diffuse large B-cell lymphomas. MYD88-L265...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minderman, Marthe, Lantermans, Hildo, van der Zwaan, Carmen, Hoogendijk, Arie J., van den Biggelaar, Maartje, Kersten, Marie José, Spaargaren, Marcel, Pals, Steven T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435502/ https://www.ncbi.nlm.nih.gov/pubmed/37591861 http://dx.doi.org/10.1038/s41408-023-00896-6

Ejemplares similares

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma
por: Lantermans, Hildo C., et al.
Publicado: (2020)

MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas
por: Minderman, Marthe, et al.
Publicado: (2023)

Schnitzler syndrome associated with MYD88 L265P mutation
por: Goodman, Aaron M., et al.
Publicado: (2019)

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014)

Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma
por: Ren, Zemin, et al.
Publicado: (2021)

The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma
por: Ren, Zemin, et al.
Publicado: (2021)

Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma
por: Rodriguez, Sara, et al.
Publicado: (2022)

Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance
por: Wang, James Q., et al.
Publicado: (2014)

MYD88 L265P mutation in intraocular lymphoma: A potential diagnostic marker
por: Narasimhan, Sandhya, et al.
Publicado: (2020)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma
por: Mori, Naoki, et al.
Publicado: (2013)

Droplet Digital PCR Assay for MYD88(L265P): Clinical Applications in Waldenström Macroglobulinemia
por: Lo Schirico, Mariella, et al.
Publicado: (2020)

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
por: Shuai, Wen, et al.
Publicado: (2020)

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
por: Kraan, W, et al.
Publicado: (2013)

Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation
por: Wang, James Q., et al.
Publicado: (2014)

MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with Waldenström Macroglobulinemia
por: Kim, Jung-Ah, et al.
Publicado: (2014)

Loss of TNFAIP3 enhances MYD88(L265P)-driven signaling in non-Hodgkin lymphoma
por: Wenzl, Kerstin, et al.
Publicado: (2018)

MYD88(L265P) Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation
por: Ferrante, Martina, et al.
Publicado: (2021)

Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88(L265P) in Waldenström Macroglobulinemia
por: Kofides, Amanda, et al.
Publicado: (2021)

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

Targeting Toll-like Receptor (TLR) Signaling by Toll/Interleukin-1 Receptor (TIR) Domain-containing Adapter Protein/MyD88 Adapter-like (TIRAP/Mal)-derived Decoy Peptides
por: Couture, Leah A., et al.
Publicado: (2012)

Inhibition of TIR Domain Signaling by TcpC: MyD88-Dependent and Independent Effects on Escherichia coli Virulence
por: Yadav, Manisha, et al.
Publicado: (2010)

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
por: Nelde, Annika, et al.
Publicado: (2016)

Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

PB2403: THE FREQUENCY OF L265P MUTATION IN MYD88 GENE AT DIFFUSE LARGE B-CELL LYMPHOMA
por: Dubrovina, Anastasiya, et al.
Publicado: (2023)

MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications
por: de Groen, Ruben A.L., et al.
Publicado: (2019)

MyD88 TIR domain higher-order assembly interactions revealed by microcrystal electron diffraction and serial femtosecond crystallography
por: Clabbers, Max T. B., et al.
Publicado: (2021)

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
por: Ansell, S M, et al.
Publicado: (2014)

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation
por: Lynch, Ryan C., et al.
Publicado: (2017)

Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia
por: Drandi, Daniela, et al.
Publicado: (2018)

Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma
por: Zorofchian, Soheil, et al.
Publicado: (2018)

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
por: Lee, Ju-Han, et al.
Publicado: (2017)

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019)

Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma
por: Yamagishi, Yuki, et al.
Publicado: (2021)

Beyond MyD88 and TRIF Pathways in Toll-Like Receptor Signaling
por: Piras, Vincent, et al.
Publicado: (2014)

Evolution of Toll, Spatzle and MyD88 in insects: the problem of the Diptera bias
por: Lima, Letícia Ferreira, et al.
Publicado: (2021)

Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma
por: Minderman, Marthe, et al.
Publicado: (2020)

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis
por: Vermaat, Joost S., et al.
Publicado: (2020)

A TIR Domain Protein from E. faecalis Attenuates MyD88-Mediated Signaling and NF-κB Activation
por: Zou, Jun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ms9qsj937q374vs67mka8bt4sc